Francoise Marvel, MD
Hospitalist · Baltimore, MDNPI 1871850198
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $58,793 of the $62,802 with a category attached, or 93.6%. Amgen accounts for 96.0% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2023 at $35,199 and has fallen 55.6% since, to $15,636 in 2025. Among hospitalist clinicians in MD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 28 payments — averaging $2242.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$60K
- Novartis$2K
- Novo Nordisk$213
- Sanofi-aventis U.S. LLC$119
Across 5 payments — averaging $21,762 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$109K
What the payments were for
- Consulting fees$58,79394%
- Travel & lodging$2,3664%
- Food & beverage$1,6433%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 24 | $60,295 |
| Novartis | 1 | $2,175 |
| Novo Nordisk | 2 | $213 |
| Sanofi-aventis U.S. LLC | 1 | $119 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$62,802 in reported general payments places this provider in the 95th percentile of 414 hospitalist providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Repatha SureclickEvolocumab | 202 | $267,421 |
| Praluent PenAlirocumab | 68 | $63,906 |
| NexletolBempedoic Acid | 40 | $35,676 |
| Ezetimibe | 150 | $7,700 |
| VascepaIcosapent Ethyl | 15 | $5,428 |
| Rosuvastatin Calcium | 52 | $973 |
| Metoprolol Succinate | 11 | $702 |
| Atorvastatin Calcium | 16 | $183 |
Paid to pharmacies, not to this prescriber.
Other hospitalist in Baltimore
- Eric RitterBaltimore$94K
- Anweshan SamantaBaltimore$24K
- Turja ChakrabartiBaltimore$6K
- Ajay HoodaBaltimore$5K
- Manu MysoreBaltimore$4K
- Nilesh PatelBaltimore$3K
- Ravitej KhunkhunBaltimore$3K
- Ericka CampbellBaltimore$3K
- Nebiyu EshetuBaltimore$3K
- Wael SultanBaltimore$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.